Minutes of Meeting of 6th APAC held on April 5, 2017

8:45-9:00 APAC CONGRATULATORY SPEECH Thomas B. Cueni, IFPMA

- I’m really honored to be able to make a speech at this 6th APAC meeting. Less than 100 days have passed since I was assigned to be the director general of IFPMA. Anyway let me give a speech on behalf of IFPMA.
- IFPMA strategically focuses on the following four areas.
  ① Securing ecosystems for sound innovation. If you want to help patients around the world, we need strong protection of intellectual property (IP) and we need have reward for innovations.
  ② Solving concerning the global health system challenges. Developing countries are facing many financial problems like developed countries. Japan and European countries are now facing aging problems. Pharmaceutical research and biologics progress is one of the answers for such aging problems.
  ③ Access to medicines is important in order to live a healthy and cheerful long life.
  ④ Business integrity (conscientiousness, completeness) is also important. IFPMA has been a pioneer in setting rules concerning the code of practice. We studied how to interact with doctors and how to improve transparency by taking them as important themes.
- Today I will talk about two main themes.
  ① IFPMA is playing major role in the debate on drug-resistant problem. This theme was taken up as a top of agenda item at G7, G20, and WHO. It is predicted that 10 million people will annually die from drug-resistant strains of bacteria by 2050. In 2016 more than 100 companies and institutions including drug companies, biologics firms, diagnostic product manufacturers, and generic drug producers signed the Davos Declaration which stated fighting against drug-resistant problems. It includes various themes such as advocating the proper use of antibacterial drugs, access to antibacterial drugs, environmental protection, and stewardship such as veterinary training in addition to specifying the development of new antibacterial drugs. JPMA and many Japanese-affiliated companies, we can say, are again able to fight against drug-resistant problem at the forefront.
  ② To set up a new project, IFPMA and multinational drug companies 23 companies met at Davos and launched the Access Accelerated project two months ago. This initiative aims to bring medicine to millions of people in low-and-middle income countries for life-threatening non-communicable disease including cancer and lifestyle-related diseases with the collaboration of companies. Many Japanese-affiliated companies are participating in this initiative, and they play a
significant role. Other than these activities, possible initiatives have been emerging, where multiple stakeholders are able to exchange their experiences at global or nation levels. A research team mainly composed of staff from Boston University is working on measuring advancements for the evolution of such initiatives. Although the above mentioned initiatives are going well, if regulatory systems work against them, we cannot properly deliver medicine to people in need. To overcome such problems, we are advancing AMRH (African Medicine Regulatory Harmonization). Persons in charge of regulatory authorities are making efforts to minimize the complexities of the system and to make regulating processes efficient and speedy by learning from experiences in other countries and having talks with industry. These issues seem to be appropriate for the agenda at this APAC meeting.

- We work on the following issues as our goals for the next three years.
  ① Demonstrate a good impact on patients' lives.
  ② Develop roadmaps for NCD treatment in developing countries.
  ③ Promote effective partnerships to advance reforms.
  ④ Arrange more sustainable care settings working together.
- I wish for great success of this APAC meeting. Thank you very much for listening.